Pioneer Hub is a practical resource for clinicians looking for clear, concise guidance on using biomarker-driven approaches in the routine care of patients with advanced prostate cancer.
In metastatic hormone-sensitive prostate cancer (mHSPC), PTEN deficiency is a prognostic biomarker that should not be overlookednot be overlooked
PTEN deficiency is associated with more aggressive mHSPC and worse outcomes, including shorter overall and progression-free survival, compared with PTEN-proficient mHSPC.1
~25%
Proportion of patients with mHSPC tumors with PTEN deficiency
11.9
months
Median overall survival of a patient with PTEN-deficient mHSPC
(compared with 30.6 months for PTEN-proficient mHSPC; p<0.001)
43.8
months
Median progression-free survival associated with PTEN-deficient mHSPC
(compared with 80.2 months for PTEN-proficient mHSPC; p<0.001)
Prostate IHC Explorer: Pathology image library
Enhance your PTEN IHC scoring confidence by reviewing a collection of real-world IHC-stained tissue samples.
View pathology images
Explore the PI3K/AKT/PTEN signaling pathway
The PI3K/AKT pathway is the most frequently disrupted signaling pathway in human cancers, contributing to tumor growth, disease progression and development of treatment resistance.2
In prostate cancer, this is often caused by a detectable deficiency of the key tumor suppressor protein, PTEN.2
Explore the pathwayBiomarker testing workflow: Clinical guidelines
Stay at the forefront of biomarker testing for metastatic prostate cancer with a simplified, step-by-step workflow integrating key recommendations from clinical guidelines.
View and download (PDF)
Explore key pages
AKT, protein kinase B; IHC, immunohistochemistry; mHSPC, metastatic hormone-sensitive prostate cancer; mTOR, mammalian target of rapamycin; PI3K, phosphoinositide 3-kinase;
PTEN, phosphatase and tensin homolog.
1. Zhang JY, et al. Asian J Androl. 2022;24(1):50–55; 2. Brown JS, Banerji U. Pharmacol Ther. 2017;172:101–115.
